Sustainability in the Manufacturing of Pharmaceuticals.

Format:

Book

Author/Creator:

Lamprou, Dimitrios A.

Language:

English

Physical Description:

1 online resource (0 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Sustainability in Pharmaceutical Manufacturing is a groundbreaking reference for the pharmaceutical industry.Currently lagging behind other manufacturing sectors, pharmaceutical production requires significant changes in areas such as manufacturing methods, waste management, packaging, and supply chain.

Contents:

Front Cover

Sustainability in the Manufacturing of Pharmaceuticals

Copyright Page

Contents

List of contributors

1 Creating a culture of sustainability

1.1 Introduction to sustainability culture in pharmaceutical manufacturing

1.2 Social and ethical responsibility in sustainable manufacturing

1.2.1 Employee engagement and workforce training in sustainable manufacturing

1.2.2 Stakeholder and community engagement in sustainable manufacturing

1.2.3 Ethical sourcing of raw materials and fair labor practices in pharmaceutical manufacturing

1.2.4 Sustainable access to medicines in sustainable pharmaceutical manufacturing

1.3 Governance and industry regulations driving sustainability

1.3.1 Sustainability reporting and metrics in sustainable pharmaceutical manufacturing

1.4 The role of payers and market demand in driving sustainability

1.4.1 Payers as catalysts for sustainable pharmaceutical manufacturing

1.4.2 Value-based pricing and sustainability incentives in pharmaceutical manufacturing

1.4.3 Market-driven sustainability: the role of patients, providers, and healthcare systems

1.4.4 Aligning economic and sustainability goals in pharma reimbursement

1.5 Initiatives in creating a culture of sustainability

1.6 Future outlook: advancing a culture of sustainability in pharmaceuticals

1.7 AI disclosure

References

2 Circular economy and life cycle management

2.1 Introduction

2.2 Discussion

2.2.1 Advancing sustainability in process development to deliver to Amgen's 2027 goals

2.2.1.1 Process development pillar 1: developing a culture of sustainability

2.2.1.2 Process development pillar 2: the importance of developing metrics to advance sustainability

2.2.1.2.1 Green biologics: metrics definition for carbon, water, and waste

2.2.1.2.2 Green synthetics metrics.

2.2.1.3 Process development pillar 3: sustainability delivered through projects

2.2.1.3.1 Biologics sustainability

2.2.1.3.2 Synthetics sustainability

2.2.1.3.3 My Green Labs and the freezer challenge

2.2.1.3.4 Sustainable green packaging

2.2.1.3.4.1 Circularity

2.2.1.3.4.2 Fewer and more sustainable plastics

2.2.1.3.4.3 Responsible sourcing

2.2.1.3.4.4 Packaging and transport reduction

2.2.1.3.4.5 Information and communication

2.3 Conclusion

Abbreviations

3 Bio-based sustainable polymers and materials

3.1 Introduction to bio-based polymers and materials

3.1.1 Background and history of bio-based polymers and materials

3.2 Sustainable polymers and materials: a need of hour

3.3 Classification and types of bio-based polymers and materials

3.3.1 Plant based

3.3.2 Microbes based

3.3.3 Animal based

3.4 Application and technological advancement of bio-based polymers and materials

3.5 Overview of bio-based polymer industries and market landscape

3.6 Life cycle assessment of bio-based polymers and materials

3.7 Recent trends, challenges, and future prospects

AI disclosure

4 Sustainability and proposals in pharmaceutical research and development: embracing innovation to overcome challenges in the global pharmaceutical landscape

4.1 The dawn of mobile health and digital biomarkers

4.1.1 Introduction

4.1.2 Mobile health and digital biomarkers

4.2 Mobile health research trends and hot spots

4.2.1 Introduction

4.2.2 Literature review of mobile health bibliometric analysis

4.2.3 Data collection

4.2.4 Data analysis

4.2.5 Trends in publications in the mobile health field

4.2.6 Trends in publications in countries and regions

4.2.7 Coauthorship networks among countries and regions.

4.2.8 Cooccurrence of keywords and networks in mobile health publications

4.2.9 Summary

4.3 The relationship between DBMs, mobile health, and drug development

4.3.1 Relationship between DBMs and drug development

4.3.2 Relationship between DBMs and Mobile Health

4.4 Cases of mobile health practical applications in Japan, China, and the United States

4.4.1 Introduction

4.4.2 MHealth practical applications

4.4.2.1 Case 1: CureApp smoking cessation of Japan

4.4.2.2 Case 2: WeDoctor of China

4.4.2.3 Case 3: Amazon Care of United States

4.4.3 Summary

4.5 Advanced research on mobile technology for drug development

4.5.1 Introduction

4.5.2 Research on the effectiveness of DBMs

4.5.2.1 Case 1: management of cardiovascular disease

4.5.2.2 Case 2: diabetes management

4.5.2.3 Case 3: managing Alzheimer's disease

4.6 Challenges and prospects of mobile health and digital biomarkers

4.6.1 About improving data quality and collection efficiency

4.6.1.1 Improving sensor technology

4.6.1.2 Optimizing data analysis

4.6.1.3 Improving data collection efficiency

4.6.2 Future drug development outlook

4.6.2.1 Case 1: the evolution of data-driven drug development

4.6.2.2 Case 2: the advancement of personalized medicine

4.6.2.3 Case 3: transforming clinical trials

4.6.2.4 Case 4: reducing healthcare costs and improving efficiency

4.6.2.5 Case 5: patient privacy and data security

4.6.3 Summary

4.7 Concluding remarks

5 Applications of microfluidics for sustainable pharmaceutical manufacturing

5.1 Introduction

5.1.1 Overview of sustainable pharmaceutical manufacturing

5.1.2 Role of microfluidics in sustainable pharmaceutical manufacturing

5.2 Fundamentals of microfluidics

5.2.1 Key components of microfluidics.

5.3 Microfluidics for pharmaceutical manufacturing

5.3.1 Microfluidic applications in pharmaceutical manufacturing

5.3.2 Microfluidics and continuous manufacturing

5.3.3 Microfluidics in personalized medicine

5.4 Sustainable impacts of microfluidic applications

5.4.1 Sustainability considerations

5.4.2 Green synthesis and process optimization

5.4.3 High-throughput screening and formulation development

5.4.4 Personalized medicine and point-of-care diagnostics

5.4.5 Organ-on-a-chip and in vitro disease modeling

5.4.6 Reduced environmental impact

5.5 Case studies and applications

5.5.1 Process intensification

5.5.2 Efficiency

5.5.2.1 Green chemistry

5.5.2.2 Waste reduction

5.5.2.3 Integration and automation

5.5.2.4 Personalized medicine

5.5.3 Biopharmaceuticals

5.5.4 Quality control and monitoring

5.6 Challenges and future directions

5.7 Multiple choice questions

5.8 Conclusions

6 3D printing the future: sustainable solutions in pharmaceutical manufacturing

6.1 Introduction

6.1.1 Overview of the pharmaceutical industry and sustainability

6.1.2 Overview of 3D printing and its relevance to various industries

6.1.2.1 History of 3D printing in healthcare and pharmaceuticals

6.1.3 Exploring how 3D printing can address sustainability in pharmaceutical manufacturing

6.2 Sustainability challenges in traditional pharmaceutical manufacturing

6.2.1 Environmental impact of conventional manufacturing

6.2.2 Resource use and material waste

6.2.3 Regulatory and economic pressures

6.3 The role of 3D printing in pharmaceutical manufacturing

6.3.1 Traditional pharmaceutical manufacturing versus 3D printing

6.3.2 Applications of 3D printing in pharmaceuticals

6.3.2.1 Personalized medicine.

6.3.2.2 On-demand manufacturing of pharmaceuticals

6.3.2.3 Drug development and prototyping

6.3.2.4 Novel drug delivery systems

6.4 Sustainable benefits of 3D printing in pharmaceuticals

6.4.1 Reduction in material waste

6.4.2 Energy efficiency

6.4.3 Distributed manufacturing and supply chain efficiency

6.4.4 Scalability and cost reduction

6.5 Case studies and real-world applications

6.6 Challenges and limitations of implementing 3D printing in pharmaceuticals

6.7 Future outlook and trends

6.8 Conclusion

7 Sustainable solutions for pharmaceutical waste

7.1 Introduction

7.2 Importance of improper disposal

7.2.1 Environmental impact

7.2.2 Water contamination

7.2.3 Soil pollution

7.3 Health risks from improper pharmaceutical disposal

7.3.1 Antibiotic resistance

7.3.2 Endocrine disruption

7.4 The need for sustainable pharmaceutical waste management

7.4.1 Waste minimization and prevention

7.4.2 Safe disposal methods

7.4.3 Recycling and reuse strategies

7.5 Role of pharmacists and healthcare professionals

7.5.1 Educating patients

7.5.2 Implementing sustainable practices

7.5.3 Policy advocacy

7.6 Sources of pharmaceutical waste

7.6.1 Production and manufacturing

7.6.2 Raw material residuals

7.6.3 Chemical by-products

7.6.4 Expired or defective batches

7.6.5 Packaging waste

7.6.6 Household waste

7.6.7 Change in prescription

7.6.8 Noncompliance

7.6.9 Over-the-counter purchases

7.7 Waste management protocols for pharmaceutical factories

7.7.1 Impact of improper disposal

7.8 Case studies of improper pharmaceutical waste disposal

7.8.1 India's antibiotic resistance crisis

7.8.2 Hormonal disruption in aquatic life

7.8.3 Drug contamination in the United States.

7.9 Innovative and emerging technologies for pharmaceutical waste management.

Notes:

Description based on publisher supplied metadata and other sources.

Other Format:

Print version: Lamprou, Dimitrios A. Sustainability in the Manufacturing of Pharmaceuticals

ISBN:

9780443289224

OCLC:

1528317180